search
Back to results

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
amlodipine
telmisartan
telmisartan and amlodipine
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  1. Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation
  2. Age 18 years or older
  3. Patients with severe hypertension as defined SBP greater than 180 mmHg and DBP greater than 95 mmHg at randomisation
  4. Ability to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigators discretion)

Exclusion criteria Mean in-clinic seated cuff SBP >/= 200 mmHg and/or Diastolic Blood Pressure [DBP] >/= 95 mmHg

Sites / Locations

  • 1235.20.525 Boehringer Ingelheim Investigational Site
  • 1235.20.503 Boehringer Ingelheim Investigational Site
  • 1235.20.507 Boehringer Ingelheim Investigational Site
  • 1235.20.529 Boehringer Ingelheim Investigational Site
  • 1235.20.518 Boehringer Ingelheim Investigational Site
  • 1235.20.521 Boehringer Ingelheim Investigational Site
  • 1235.20.508 Boehringer Ingelheim Investigational Site
  • 1235.20.506 Boehringer Ingelheim Investigational Site
  • 1235.20.519 Boehringer Ingelheim Investigational Site
  • 1235.20.523 Boehringer Ingelheim Investigational Site
  • 1235.20.528 Boehringer Ingelheim Investigational Site
  • 1235.20.516 Boehringer Ingelheim Investigational Site
  • 1235.20.527 Boehringer Ingelheim Investigational Site
  • 1235.20.510 Boehringer Ingelheim Investigational Site
  • 1235.20.512 Boehringer Ingelheim Investigational Site
  • 1235.20.509 Boehringer Ingelheim Investigational Site
  • 1235.20.511 Boehringer Ingelheim Investigational Site
  • 1235.20.515 Boehringer Ingelheim Investigational Site
  • 1235.20.534 Boehringer Ingelheim Investigational Site
  • 1235.20.526 Boehringer Ingelheim Investigational Site
  • 1235.20.513 Boehringer Ingelheim Investigational Site
  • 1235.20.517 Boehringer Ingelheim Investigational Site
  • 1235.20.522 Boehringer Ingelheim Investigational Site
  • 1235.20.520 Boehringer Ingelheim Investigational Site
  • 1235.20.530 Boehringer Ingelheim Investigational Site
  • 1235.20.535 Boehringer Ingelheim Investigational Site
  • 1235.20.533 Boehringer Ingelheim Investigational Site
  • 1235.20.505 Boehringer Ingelheim Investigational Site
  • 1235.20.537 Boehringer Ingelheim Investigational Site
  • 1235.20.501 Boehringer Ingelheim Investigational Site
  • 1235.20.001 Boehringer Ingelheim Investigational Site
  • 1235.20.002 Boehringer Ingelheim Investigational Site
  • 1235.20.003 Boehringer Ingelheim Investigational Site
  • 1235.20.005 Boehringer Ingelheim Investigational Site
  • 1235.20.006 Boehringer Ingelheim Investigational Site
  • 1235.20.007 Boehringer Ingelheim Investigational Site
  • 1235.20.008 Boehringer Ingelheim Investigational Site
  • 1235.20.009 Boehringer Ingelheim Investigational Site
  • 1235.20.004 Boehringer Ingelheim Investigational Site
  • 1235.20.052 Boehringer Ingelheim Investigational Site
  • 1235.20.059 Boehringer Ingelheim Investigational Site
  • 1235.20.051 Boehringer Ingelheim Investigational Site
  • 1235.20.053 Boehringer Ingelheim Investigational Site
  • 1235.20.054 Boehringer Ingelheim Investigational Site
  • 1235.20.055 Boehringer Ingelheim Investigational Site
  • 1235.20.057 Boehringer Ingelheim Investigational Site
  • 1235.20.058 Boehringer Ingelheim Investigational Site
  • 1235.20.101A Boehringer Ingelheim Investigational Site
  • 1235.20.102F Boehringer Ingelheim Investigational Site
  • 1235.20.103A Boehringer Ingelheim Investigational Site
  • 1235.20.103C Boehringer Ingelheim Investigational Site
  • 1235.20.103F Boehringer Ingelheim Investigational Site
  • 1235.20.106A Boehringer Ingelheim Investigational Site
  • 1235.20.109B Boehringer Ingelheim Investigational Site
  • 1235.20.108E Boehringer Ingelheim Investigational Site
  • 1235.20.101D Boehringer Ingelheim Investigational Site
  • 1235.20.103E Boehringer Ingelheim Investigational Site
  • 1235.20.108C Boehringer Ingelheim Investigational Site
  • 1235.20.106D Boehringer Ingelheim Investigational Site
  • 1235.20.108F Boehringer Ingelheim Investigational Site
  • 1235.20.102A Boehringer Ingelheim Investigational Site
  • 1235.20.102C Boehringer Ingelheim Investigational Site
  • 1235.20.101C Boehringer Ingelheim Investigational Site
  • 1235.20.108A Boehringer Ingelheim Investigational Site
  • 1235.20.108B Boehringer Ingelheim Investigational Site
  • 1235.20.106F Boehringer Ingelheim Investigational Site
  • 1235.20.102E Boehringer Ingelheim Investigational Site
  • 1235.20.106B Boehringer Ingelheim Investigational Site
  • 1235.20.107A Boehringer Ingelheim Investigational Site
  • 1235.20.107B Boehringer Ingelheim Investigational Site
  • 1235.20.107E Boehringer Ingelheim Investigational Site
  • 1235.20.107G Boehringer Ingelheim Investigational Site
  • 1235.20.109A Boehringer Ingelheim Investigational Site
  • 1235.20.109F Boehringer Ingelheim Investigational Site
  • 1235.20.104A Boehringer Ingelheim Investigational Site
  • 1235.20.104D Boehringer Ingelheim Investigational Site
  • 1235.20.107F Boehringer Ingelheim Investigational Site
  • 1235.20.105A Boehringer Ingelheim Investigational Site
  • 1235.20.105D Boehringer Ingelheim Investigational Site
  • 1235.20.152 Boehringer Ingelheim Investigational Site
  • 1235.20.156 Boehringer Ingelheim Investigational Site
  • 1235.20.158 Boehringer Ingelheim Investigational Site
  • 1235.20.159 Boehringer Ingelheim Investigational Site
  • 1235.20.161 Boehringer Ingelheim Investigational Site
  • 1235.20.153 Boehringer Ingelheim Investigational Site
  • 1235.20.154 Boehringer Ingelheim Investigational Site
  • 1235.20.157 Boehringer Ingelheim Investigational Site
  • 1235.20.155 Boehringer Ingelheim Investigational Site
  • 1235.20.207 Boehringer Ingelheim Investigational Site
  • 1235.20.206 Boehringer Ingelheim Investigational Site
  • 1235.20.205 Boehringer Ingelheim Investigational Site
  • 1235.20.201 Boehringer Ingelheim Investigational Site
  • 1235.20.202 Boehringer Ingelheim Investigational Site
  • 1235.20.203 Boehringer Ingelheim Investigational Site
  • 1235.20.204 Boehringer Ingelheim Investigational Site
  • 1235.20.252 Boehringer Ingelheim Investigational Site
  • 1235.20.259 Boehringer Ingelheim Investigational Site
  • 1235.20.262 Boehringer Ingelheim Investigational Site
  • 1235.20.254 Boehringer Ingelheim Investigational Site
  • 1235.20.261 Boehringer Ingelheim Investigational Site
  • 1235.20.256 Boehringer Ingelheim Investigational Site
  • 1235.20.251 Boehringer Ingelheim Investigational Site
  • 1235.20.260 Boehringer Ingelheim Investigational Site
  • 1235.20.253 Boehringer Ingelheim Investigational Site
  • 1235.20.301 Boehringer Ingelheim Investigational Site
  • 1235.20.302 Boehringer Ingelheim Investigational Site
  • 1235.20.303 Boehringer Ingelheim Investigational Site
  • 1235.20.304 Boehringer Ingelheim Investigational Site
  • 1235.20.310 Boehringer Ingelheim Investigational Site
  • 1235.20.305 Boehringer Ingelheim Investigational Site
  • 1235.20.306 Boehringer Ingelheim Investigational Site
  • 1235.20.307 Boehringer Ingelheim Investigational Site
  • 1235.20.308 Boehringer Ingelheim Investigational Site
  • 1235.20.309 Boehringer Ingelheim Investigational Site
  • 1235.20.311 Boehringer Ingelheim Investigational Site
  • 1235.20.355 Boehringer Ingelheim Investigational Site
  • 1235.20.353 Boehringer Ingelheim Investigational Site
  • 1235.20.352 Boehringer Ingelheim Investigational Site
  • 1235.20.354 Boehringer Ingelheim Investigational Site
  • 1235.20.356 Boehringer Ingelheim Investigational Site
  • 1235.20.351 Boehringer Ingelheim Investigational Site
  • 1235.20.406 Boehringer Ingelheim Investigational Site
  • 1235.20.408 Boehringer Ingelheim Investigational Site
  • 1235.20.402 Boehringer Ingelheim Investigational Site
  • 1235.20.403 Boehringer Ingelheim Investigational Site
  • 1235.20.409 Boehringer Ingelheim Investigational Site
  • 1235.20.451 Boehringer Ingelheim Investigational Site
  • 1235.20.458 Boehringer Ingelheim Investigational Site
  • 1235.20.460 Boehringer Ingelheim Investigational Site
  • 1235.20.453 Boehringer Ingelheim Investigational Site
  • 1235.20.454 Boehringer Ingelheim Investigational Site
  • 1235.20.455 Boehringer Ingelheim Investigational Site
  • 1235.20.456 Boehringer Ingelheim Investigational Site
  • 1235.20.457 Boehringer Ingelheim Investigational Site
  • 1235.20.461 Boehringer Ingelheim Investigational Site
  • 1235.20.452 Boehringer Ingelheim Investigational Site
  • 1235.20.459 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

telmisartan and amlodipine

amlodipine

telmisartan

Arm Description

telmisartan and amlodipine used in combination vs amlodipine or telmisartan

telmisartan and amlodipine used in combination vs amlodipine or telmisartan

telmisartan and amlodipine used in combination vs amlodipine or telmisartan

Outcomes

Primary Outcome Measures

Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8
Overall mean reduction from a common mean baseline in SBP

Secondary Outcome Measures

Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6
Overall mean reduction from a common mean baseline in SBP
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4
Overall mean reduction from a common mean baseline in SBP
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2
Overall mean reduction from a common mean baseline in SBP
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1
Overall mean reduction from a common mean baseline in SBP
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8
Overall mean reduction from a common mean baseline in DBP
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6
Overall mean reduction from a common mean baseline in DBP
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4
Overall mean reduction from a common mean baseline in DBP
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2
Overall mean reduction from a common mean baseline in DBP
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1
Overall mean reduction from a common mean baseline in DBP
Patients Achieving Diastolic Blood Pressure Control at Week 1
Diastolic Blood Pressure Control is defined as achieving DBP < 90mmHg
Patients Achieving Diastolic Blood Pressure Control at Week 2
DBP < 90 mmHg
Patients Achieving Blood Pressure Control at Week 1
Blood Pressure Control is defined as achieving SBP< 140 mmHg and DBP < 90mmHg
Patients Achieving Blood Pressure Control at Week 2
SBP < 140 mmHg and DBP < 90 mmHg
Patients Achieving Diastolic Blood Pressure Response at Week 1
Diastolic Blood Pressure Response is defined as achieving DBP < 90 mmHg or a reduction of >= 10 mmHg
Patients Achieving Diastolic Blood Pressure Response at Week 2
DBP < 90 mmHg or reduction of >= 10 mmHg
Patients Achieving Systolic Blood Pressure Response at Week 1
Systolic Blood Pressure Response Control is defined as achieving SBP < 140 mmHg or a reduction of >= 15 mmHg
Patients Achieving Systolic Blood Pressure Response at Week 2
SBP < 140 mmHg or reduction of >= 15 mmHg
Number of Patients Achieving Various Blood Pressure Response Levels at Week 1
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Number of Patients Achieving Various Blood Pressure Response Levels at Week 2
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Patients Achieving Diastolic Blood Pressure Control at Week 4
DBP < 90 mmHg
Patients Achieving Diastolic Blood Pressure Control at Week 6
DBP < 90 mmHg
Patients Achieving Diastolic Blood Pressure Control at Week 8
DBP < 90 mmHg
Patients Achieving Blood Pressure Control at Week 4
SBP < 140 mmHg and DBP < 90 mmHg
Patients Achieving Blood Pressure Control at Week 6
SBP < 140 mmHg and DBP < 90 mmHg
Patients Achieving Blood Pressure Control at Week 8
SBP < 140 mmHg and DBP < 90 mmHg
Patients Achieving Diastolic Blood Pressure Response at Week 4
DBP < 90 mmHg or reduction of >= 10 mmHg
Patients Achieving Diastolic Blood Pressure Response at Week 6
DBP < 90 mmHg or reduction of >= 10 mmHg
Patients Achieving Diastolic Blood Pressure Response at Week 8
DBP < 90 mmHg or reduction of >= 10 mmHg
Patients Achieving Systolic Blood Pressure Response at Week 4
SBP < 140 mmHg or reduction of >= 15 mmHg
Patients Achieving Systolic Blood Pressure Response at Week 6
SBP < 140 mmHg or reduction of >= 15 mmHg
Patients Achieving Systolic Blood Pressure Response at Week 8
SBP < 140 mmHg or reduction of >= 15 mmHg
Patients Achieving Normal Blood Pressure Response at Week 4
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Patients Achieving Normal Blood Pressure Response at Week 6
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Patients Achieving Normal Blood Pressure Response at Week 8
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90

Full Information

First Posted
March 11, 2009
Last Updated
May 16, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00860262
Brief Title
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
Official Title
An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg & Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The primary objective of this trial is to demonstrate that following eight weeks of treatment the FDC of telmisartan 80 mg plus amlodipine 10 mg (T80/A10) is superior as first line therapy in reducing mean seated trough cuff Systolic Blood Pressure [SBP] compared to the monotherapies of telmisartan 80 mg (T80) and amlodipine 10 mg (A10) in patients with severe hypertension. A key secondary objective is to identify the duration of treatment required to demonstrate the superiority of the FDC over both of the monotherapies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
858 (Actual)

8. Arms, Groups, and Interventions

Arm Title
telmisartan and amlodipine
Arm Type
Experimental
Arm Description
telmisartan and amlodipine used in combination vs amlodipine or telmisartan
Arm Title
amlodipine
Arm Type
Active Comparator
Arm Description
telmisartan and amlodipine used in combination vs amlodipine or telmisartan
Arm Title
telmisartan
Arm Type
Active Comparator
Arm Description
telmisartan and amlodipine used in combination vs amlodipine or telmisartan
Intervention Type
Drug
Intervention Name(s)
amlodipine
Intervention Description
amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
Intervention Type
Drug
Intervention Name(s)
telmisartan
Intervention Description
telmisartan 80mg for the 8w, no titration required
Intervention Type
Drug
Intervention Name(s)
telmisartan and amlodipine
Intervention Description
telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
Primary Outcome Measure Information:
Title
Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8
Description
Overall mean reduction from a common mean baseline in SBP
Time Frame
baseline and week 8
Secondary Outcome Measure Information:
Title
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6
Description
Overall mean reduction from a common mean baseline in SBP
Time Frame
baseline and week 6
Title
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4
Description
Overall mean reduction from a common mean baseline in SBP
Time Frame
baseline and week 4
Title
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2
Description
Overall mean reduction from a common mean baseline in SBP
Time Frame
baseline and week 2
Title
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1
Description
Overall mean reduction from a common mean baseline in SBP
Time Frame
baseline and week 1
Title
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8
Description
Overall mean reduction from a common mean baseline in DBP
Time Frame
baseline and week 8
Title
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6
Description
Overall mean reduction from a common mean baseline in DBP
Time Frame
baseline and week 6
Title
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4
Description
Overall mean reduction from a common mean baseline in DBP
Time Frame
baseline and week 4
Title
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2
Description
Overall mean reduction from a common mean baseline in DBP
Time Frame
baseline and week 2
Title
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1
Description
Overall mean reduction from a common mean baseline in DBP
Time Frame
baseline and week 1
Title
Patients Achieving Diastolic Blood Pressure Control at Week 1
Description
Diastolic Blood Pressure Control is defined as achieving DBP < 90mmHg
Time Frame
week 1
Title
Patients Achieving Diastolic Blood Pressure Control at Week 2
Description
DBP < 90 mmHg
Time Frame
week 2
Title
Patients Achieving Blood Pressure Control at Week 1
Description
Blood Pressure Control is defined as achieving SBP< 140 mmHg and DBP < 90mmHg
Time Frame
week 1
Title
Patients Achieving Blood Pressure Control at Week 2
Description
SBP < 140 mmHg and DBP < 90 mmHg
Time Frame
week 2
Title
Patients Achieving Diastolic Blood Pressure Response at Week 1
Description
Diastolic Blood Pressure Response is defined as achieving DBP < 90 mmHg or a reduction of >= 10 mmHg
Time Frame
baseline, week 1
Title
Patients Achieving Diastolic Blood Pressure Response at Week 2
Description
DBP < 90 mmHg or reduction of >= 10 mmHg
Time Frame
baseline, week 2
Title
Patients Achieving Systolic Blood Pressure Response at Week 1
Description
Systolic Blood Pressure Response Control is defined as achieving SBP < 140 mmHg or a reduction of >= 15 mmHg
Time Frame
baseline, week 1
Title
Patients Achieving Systolic Blood Pressure Response at Week 2
Description
SBP < 140 mmHg or reduction of >= 15 mmHg
Time Frame
baseline, week 2
Title
Number of Patients Achieving Various Blood Pressure Response Levels at Week 1
Description
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Time Frame
week 1
Title
Number of Patients Achieving Various Blood Pressure Response Levels at Week 2
Description
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Time Frame
week 2
Title
Patients Achieving Diastolic Blood Pressure Control at Week 4
Description
DBP < 90 mmHg
Time Frame
week 4
Title
Patients Achieving Diastolic Blood Pressure Control at Week 6
Description
DBP < 90 mmHg
Time Frame
week 6
Title
Patients Achieving Diastolic Blood Pressure Control at Week 8
Description
DBP < 90 mmHg
Time Frame
week 8
Title
Patients Achieving Blood Pressure Control at Week 4
Description
SBP < 140 mmHg and DBP < 90 mmHg
Time Frame
week 4
Title
Patients Achieving Blood Pressure Control at Week 6
Description
SBP < 140 mmHg and DBP < 90 mmHg
Time Frame
week 6
Title
Patients Achieving Blood Pressure Control at Week 8
Description
SBP < 140 mmHg and DBP < 90 mmHg
Time Frame
week 8
Title
Patients Achieving Diastolic Blood Pressure Response at Week 4
Description
DBP < 90 mmHg or reduction of >= 10 mmHg
Time Frame
baseline, week 4
Title
Patients Achieving Diastolic Blood Pressure Response at Week 6
Description
DBP < 90 mmHg or reduction of >= 10 mmHg
Time Frame
baseline, week 6
Title
Patients Achieving Diastolic Blood Pressure Response at Week 8
Description
DBP < 90 mmHg or reduction of >= 10 mmHg
Time Frame
baseline, week 8
Title
Patients Achieving Systolic Blood Pressure Response at Week 4
Description
SBP < 140 mmHg or reduction of >= 15 mmHg
Time Frame
baseline, week 4
Title
Patients Achieving Systolic Blood Pressure Response at Week 6
Description
SBP < 140 mmHg or reduction of >= 15 mmHg
Time Frame
baseline, week 6
Title
Patients Achieving Systolic Blood Pressure Response at Week 8
Description
SBP < 140 mmHg or reduction of >= 15 mmHg
Time Frame
baseline, week 8
Title
Patients Achieving Normal Blood Pressure Response at Week 4
Description
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Time Frame
week 4
Title
Patients Achieving Normal Blood Pressure Response at Week 6
Description
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Time Frame
week 6
Title
Patients Achieving Normal Blood Pressure Response at Week 8
Description
Optimal: SBP<120 and DBP< 80; Normal: 120<=SBP<130 and 80<= DBP<85; High normal: 130<=SBP<140 and 85<=DBP<90; High: SBP>=140 or DBP>=90
Time Frame
week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation Age 18 years or older Patients with severe hypertension as defined SBP greater than 180 mmHg and DBP greater than 95 mmHg at randomisation Ability to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigators discretion) Exclusion criteria Mean in-clinic seated cuff SBP >/= 200 mmHg and/or Diastolic Blood Pressure [DBP] >/= 95 mmHg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1235.20.525 Boehringer Ingelheim Investigational Site
City
Buena Park
State/Province
California
Country
United States
Facility Name
1235.20.503 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
1235.20.507 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
1235.20.529 Boehringer Ingelheim Investigational Site
City
Roseville
State/Province
California
Country
United States
Facility Name
1235.20.518 Boehringer Ingelheim Investigational Site
City
Tustin
State/Province
California
Country
United States
Facility Name
1235.20.521 Boehringer Ingelheim Investigational Site
City
Westlake Village
State/Province
California
Country
United States
Facility Name
1235.20.508 Boehringer Ingelheim Investigational Site
City
DeLand
State/Province
Florida
Country
United States
Facility Name
1235.20.506 Boehringer Ingelheim Investigational Site
City
Hialeah
State/Province
Florida
Country
United States
Facility Name
1235.20.519 Boehringer Ingelheim Investigational Site
City
Pembroke Pines
State/Province
Florida
Country
United States
Facility Name
1235.20.523 Boehringer Ingelheim Investigational Site
City
Port Orange
State/Province
Florida
Country
United States
Facility Name
1235.20.528 Boehringer Ingelheim Investigational Site
City
Blue Ridge
State/Province
Georgia
Country
United States
Facility Name
1235.20.516 Boehringer Ingelheim Investigational Site
City
North Dartmouth
State/Province
Massachusetts
Country
United States
Facility Name
1235.20.527 Boehringer Ingelheim Investigational Site
City
Bay City
State/Province
Michigan
Country
United States
Facility Name
1235.20.510 Boehringer Ingelheim Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
1235.20.512 Boehringer Ingelheim Investigational Site
City
Albuquerque
State/Province
New Mexico
Country
United States
Facility Name
1235.20.509 Boehringer Ingelheim Investigational Site
City
Bronx
State/Province
New York
Country
United States
Facility Name
1235.20.511 Boehringer Ingelheim Investigational Site
City
Kettering
State/Province
Ohio
Country
United States
Facility Name
1235.20.515 Boehringer Ingelheim Investigational Site
City
Tulsa
State/Province
Oklahoma
Country
United States
Facility Name
1235.20.534 Boehringer Ingelheim Investigational Site
City
Medford
State/Province
Oregon
Country
United States
Facility Name
1235.20.526 Boehringer Ingelheim Investigational Site
City
Erie
State/Province
Pennsylvania
Country
United States
Facility Name
1235.20.513 Boehringer Ingelheim Investigational Site
City
Tipton
State/Province
Pennsylvania
Country
United States
Facility Name
1235.20.517 Boehringer Ingelheim Investigational Site
City
Providence
State/Province
Rhode Island
Country
United States
Facility Name
1235.20.522 Boehringer Ingelheim Investigational Site
City
Carrollton
State/Province
Texas
Country
United States
Facility Name
1235.20.520 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1235.20.530 Boehringer Ingelheim Investigational Site
City
Killeen
State/Province
Texas
Country
United States
Facility Name
1235.20.535 Boehringer Ingelheim Investigational Site
City
Draper
State/Province
Utah
Country
United States
Facility Name
1235.20.533 Boehringer Ingelheim Investigational Site
City
Magna
State/Province
Utah
Country
United States
Facility Name
1235.20.505 Boehringer Ingelheim Investigational Site
City
Saratoga Springs
State/Province
Utah
Country
United States
Facility Name
1235.20.537 Boehringer Ingelheim Investigational Site
City
Tacoma
State/Province
Washington
Country
United States
Facility Name
1235.20.501 Boehringer Ingelheim Investigational Site
City
Madison
State/Province
Wisconsin
Country
United States
Facility Name
1235.20.001 Boehringer Ingelheim Investigational Site
City
Bourgas
Country
Bulgaria
Facility Name
1235.20.002 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1235.20.003 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1235.20.005 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1235.20.006 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1235.20.007 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1235.20.008 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1235.20.009 Boehringer Ingelheim Investigational Site
City
Sofia
Country
Bulgaria
Facility Name
1235.20.004 Boehringer Ingelheim Investigational Site
City
Stara Zagora
Country
Bulgaria
Facility Name
1235.20.052 Boehringer Ingelheim Investigational Site
City
Benatky nad Jizerou
Country
Czech Republic
Facility Name
1235.20.059 Boehringer Ingelheim Investigational Site
City
Cesky Krumlov
Country
Czech Republic
Facility Name
1235.20.051 Boehringer Ingelheim Investigational Site
City
Plzen
Country
Czech Republic
Facility Name
1235.20.053 Boehringer Ingelheim Investigational Site
City
Praha 5
Country
Czech Republic
Facility Name
1235.20.054 Boehringer Ingelheim Investigational Site
City
Pribram
Country
Czech Republic
Facility Name
1235.20.055 Boehringer Ingelheim Investigational Site
City
Slany
Country
Czech Republic
Facility Name
1235.20.057 Boehringer Ingelheim Investigational Site
City
Strakonice
Country
Czech Republic
Facility Name
1235.20.058 Boehringer Ingelheim Investigational Site
City
Tabor
Country
Czech Republic
Facility Name
1235.20.101A Boehringer Ingelheim Investigational Site
City
Albens
Country
France
Facility Name
1235.20.102F Boehringer Ingelheim Investigational Site
City
Arles
Country
France
Facility Name
1235.20.103A Boehringer Ingelheim Investigational Site
City
Beziers
Country
France
Facility Name
1235.20.103C Boehringer Ingelheim Investigational Site
City
Beziers
Country
France
Facility Name
1235.20.103F Boehringer Ingelheim Investigational Site
City
Beziers
Country
France
Facility Name
1235.20.106A Boehringer Ingelheim Investigational Site
City
Bourg des cptes
Country
France
Facility Name
1235.20.109B Boehringer Ingelheim Investigational Site
City
Brive
Country
France
Facility Name
1235.20.108E Boehringer Ingelheim Investigational Site
City
Carbonne
Country
France
Facility Name
1235.20.101D Boehringer Ingelheim Investigational Site
City
Chambery
Country
France
Facility Name
1235.20.103E Boehringer Ingelheim Investigational Site
City
Cournonterral
Country
France
Facility Name
1235.20.108C Boehringer Ingelheim Investigational Site
City
Cugnaux
Country
France
Facility Name
1235.20.106D Boehringer Ingelheim Investigational Site
City
Etrelles
Country
France
Facility Name
1235.20.108F Boehringer Ingelheim Investigational Site
City
Fenouillet
Country
France
Facility Name
1235.20.102A Boehringer Ingelheim Investigational Site
City
Gemenos
Country
France
Facility Name
1235.20.102C Boehringer Ingelheim Investigational Site
City
Gemenos
Country
France
Facility Name
1235.20.101C Boehringer Ingelheim Investigational Site
City
Gresy Sur Aix
Country
France
Facility Name
1235.20.108A Boehringer Ingelheim Investigational Site
City
Labarthe Sur Leze
Country
France
Facility Name
1235.20.108B Boehringer Ingelheim Investigational Site
City
Labarthe sur Leze
Country
France
Facility Name
1235.20.106F Boehringer Ingelheim Investigational Site
City
Louvigne De bais
Country
France
Facility Name
1235.20.102E Boehringer Ingelheim Investigational Site
City
Marseille
Country
France
Facility Name
1235.20.106B Boehringer Ingelheim Investigational Site
City
Mordelles
Country
France
Facility Name
1235.20.107A Boehringer Ingelheim Investigational Site
City
Ortez
Country
France
Facility Name
1235.20.107B Boehringer Ingelheim Investigational Site
City
Orthez
Country
France
Facility Name
1235.20.107E Boehringer Ingelheim Investigational Site
City
Orthez
Country
France
Facility Name
1235.20.107G Boehringer Ingelheim Investigational Site
City
Orthez
Country
France
Facility Name
1235.20.109A Boehringer Ingelheim Investigational Site
City
Rosiers d'Egletons
Country
France
Facility Name
1235.20.109F Boehringer Ingelheim Investigational Site
City
Saint Aulaire
Country
France
Facility Name
1235.20.104A Boehringer Ingelheim Investigational Site
City
Saint Etienne
Country
France
Facility Name
1235.20.104D Boehringer Ingelheim Investigational Site
City
Saint Etienne
Country
France
Facility Name
1235.20.107F Boehringer Ingelheim Investigational Site
City
Salies de Bearn
Country
France
Facility Name
1235.20.105A Boehringer Ingelheim Investigational Site
City
Toulon
Country
France
Facility Name
1235.20.105D Boehringer Ingelheim Investigational Site
City
Toulon
Country
France
Facility Name
1235.20.152 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1235.20.156 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1235.20.158 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1235.20.159 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1235.20.161 Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
1235.20.153 Boehringer Ingelheim Investigational Site
City
Gyongyos
Country
Hungary
Facility Name
1235.20.154 Boehringer Ingelheim Investigational Site
City
Miskolc
Country
Hungary
Facility Name
1235.20.157 Boehringer Ingelheim Investigational Site
City
Miskolc
Country
Hungary
Facility Name
1235.20.155 Boehringer Ingelheim Investigational Site
City
Mosonmagyarovar
Country
Hungary
Facility Name
1235.20.207 Boehringer Ingelheim Investigational Site
City
Busan
Country
Korea, Republic of
Facility Name
1235.20.206 Boehringer Ingelheim Investigational Site
City
Chunan
Country
Korea, Republic of
Facility Name
1235.20.205 Boehringer Ingelheim Investigational Site
City
Koyang
Country
Korea, Republic of
Facility Name
1235.20.201 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.20.202 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.20.203 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.20.204 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1235.20.252 Boehringer Ingelheim Investigational Site
City
Braila
Country
Romania
Facility Name
1235.20.259 Boehringer Ingelheim Investigational Site
City
Bucharest
Country
Romania
Facility Name
1235.20.262 Boehringer Ingelheim Investigational Site
City
Bucharest
Country
Romania
Facility Name
1235.20.254 Boehringer Ingelheim Investigational Site
City
Iasi
Country
Romania
Facility Name
1235.20.261 Boehringer Ingelheim Investigational Site
City
Oradea
Country
Romania
Facility Name
1235.20.256 Boehringer Ingelheim Investigational Site
City
Sibiu
Country
Romania
Facility Name
1235.20.251 Boehringer Ingelheim Investigational Site
City
Targu-Mures
Country
Romania
Facility Name
1235.20.260 Boehringer Ingelheim Investigational Site
City
Tg. Mures
Country
Romania
Facility Name
1235.20.253 Boehringer Ingelheim Investigational Site
City
Timisoara
Country
Romania
Facility Name
1235.20.301 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1235.20.302 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1235.20.303 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1235.20.304 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1235.20.310 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1235.20.305 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1235.20.306 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1235.20.307 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1235.20.308 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1235.20.309 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1235.20.311 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1235.20.355 Boehringer Ingelheim Investigational Site
City
Galanta
Country
Slovakia
Facility Name
1235.20.353 Boehringer Ingelheim Investigational Site
City
Kosice
Country
Slovakia
Facility Name
1235.20.352 Boehringer Ingelheim Investigational Site
City
Povazska Bystrica
Country
Slovakia
Facility Name
1235.20.354 Boehringer Ingelheim Investigational Site
City
Rimavska Sobota
Country
Slovakia
Facility Name
1235.20.356 Boehringer Ingelheim Investigational Site
City
Trnava
Country
Slovakia
Facility Name
1235.20.351 Boehringer Ingelheim Investigational Site
City
Vrable
Country
Slovakia
Facility Name
1235.20.406 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1235.20.408 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1235.20.402 Boehringer Ingelheim Investigational Site
City
Granada
Country
Spain
Facility Name
1235.20.403 Boehringer Ingelheim Investigational Site
City
Sevilla
Country
Spain
Facility Name
1235.20.409 Boehringer Ingelheim Investigational Site
City
Valencia
Country
Spain
Facility Name
1235.20.451 Boehringer Ingelheim Investigational Site
City
Kharkov
Country
Ukraine
Facility Name
1235.20.458 Boehringer Ingelheim Investigational Site
City
Kharkov
Country
Ukraine
Facility Name
1235.20.460 Boehringer Ingelheim Investigational Site
City
Kharkov
Country
Ukraine
Facility Name
1235.20.453 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1235.20.454 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1235.20.455 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1235.20.456 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1235.20.457 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1235.20.461 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1235.20.452 Boehringer Ingelheim Investigational Site
City
Lvov
Country
Ukraine
Facility Name
1235.20.459 Boehringer Ingelheim Investigational Site
City
Odessa
Country
Ukraine

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.20_U10-3292.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1235/1235.20_literature.pdf
Description
Related Info

Learn more about this trial

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

We'll reach out to this number within 24 hrs